Brief: Tonix Pharmaceuticals Announces Licensing TNX-4900
16/12/2025 12:07
Dec 16 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES LICENSING TNX-4900, A SELECTIVE SIGMA-1 RECEPTOR ANTAGONIST FOR CHRONIC NEUROPATHIC PAIN FROM RUTGERS UNIVERSITY Source text: ID:nGNX4QZzZp Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview